We use tools such as Google Analytics, Hotjar, Google Optimize and Loop11 to help us anonymously measure how you use our websites. This allows us to make improvements based on our users' needs.

The London School of Economics and Political Science (LSE) have joined forces with NICE to offer a unique solution - the Executive MSc in Healthcare Decision-Making.

We have also today published a new discussion aid to support shared decision making about HRT, focusing on the key risks and benefits to consider. The guideline clarifies that whilst HRT has some ...

The 4 technology appraisal committees are standing advisory committees of NICE. This topic was considered by committee C. Committee members are asked to declare any interests in the technology being ...

Your organisation needs to be registered as a stakeholder before we can accept comments. Not eligible? Contact the stakeholder organisation that most closely represents your interests and pass your ...

Avapritinib (Ayvakyt) is indicated 'as monotherapy for the treatment of adult patients with aggressive systemic mastocytosis (ASM), systemic mastocytosis with an associated haematological neoplasm (SM ...

The guideline recommends that for some women, trans men and non-binary people registered female at birth, additional advice should be sought from a healthcare professional with expertise in menopause ...

To find NICE guidance on related topics, including guidance in development, see the NICE topic page on menopause. For full details of the evidence and the guideline committee's discussions, see the ...

The November 2024 version of NICE's guideline on menopause updates and replaces the previous version published in November 2015. New evidence reviewed included information on endometrial cancer, ...

Suggested remit: To appraise the clinical and cost effectiveness of talquetamab within its marketing authorisation for treating relapsed or refractory multiple myeloma after 3 treatments.

Avapritinib is recommended, within its marketing authorisation, as an option for treating advanced systemic mastocytosis (including aggressive systemic mastocytosis, systemic mastocytosis with an ...